skip to main content
Idioma:
Resultados 1 2 3 4 next page
Refinado por: Nome da Publicação: Annals Of Oncology remover assunto: Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

Font, A. ; Taron, M. ; Gago, J.L. ; Costa, C. ; Sánchez, J.J. ; Carrato, C. ; Mora, M. ; Celiz, P. ; Perez, L. ; Rodríguez, D. ; Gimenez-Capitan, A. ; Quiroga, V. ; Benlloch, S. ; Ibarz, L. ; Rosell, R.

Annals of oncology, 2011-01, Vol.22 (1), p.139-144 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours
Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours

Santos, L. ; Costa, C. ; Pereira, S. ; Koch, M. ; Amaro, T. ; Cardoso, F. ; Guimarães, T. ; Bento, M. J. ; Lobo, F. ; Pinto, S. ; Lopes, C.

Annals of oncology, 2003-09, Vol.14 (9), p.1419-1424 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível

Citações Citado por
3
A simple cost-effective lactate dehydrogenase level measurement can stratify patients with Ewing’s tumor into low and high risk
A simple cost-effective lactate dehydrogenase level measurement can stratify patients with Ewing’s tumor into low and high risk
Material Type:
Artigo 		Adicionar ao Meu Espaço

A simple cost-effective lactate dehydrogenase level measurement can stratify patients with Ewing’s tumor into low and high risk

da Costa, C. M. L. ; Lopes, A. ; de Camargo, B.

Annals of oncology, 2003-04, Vol.14 (4), p.656-656 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
4
Are PubMed alone and English literature only enough for a meta-analysis?
Are PubMed alone and English literature only enough for a meta-analysis?
Material Type:
Artigo 		Adicionar ao Meu Espaço

Are PubMed alone and English literature only enough for a meta-analysis?

Zheng, B. ; Zheng, W. ; Zhu, Y. ; Guo, C. ; Wu, W. ; Chen, C.

Annals of oncology, 2013-04, Vol.24 (4), p.1130-1130 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

von Minckwitz, G. ; Rezai, M. ; Fasching, P.A. ; Huober, J. ; Tesch, H. ; Bauerfeind, I. ; Hilfrich, J. ; Eidtmann, H. ; Gerber, B. ; Hanusch, C. ; Blohmer, J.U. ; Costa, S.D. ; Jackisch, C. ; Paepke, S. ; Schneeweiss, A. ; Kümmel, S. ; Denkert, C. ; Mehta, K. ; Loibl, S. ; Untch, M.

Annals of oncology, 2014-01, Vol.25 (1), p.81-89 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Material Type:
Artigo 		Adicionar ao Meu Espaço

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Cardoso, F ; Senkus, E ; Costa, A ; Papadopoulos, E ; Aapro, M ; André, F ; Harbeck, N ; Aguilar Lopez, B ; Barrios, C H ; Bergh, J ; Biganzoli, L ; Boers-Doets, C B ; Cardoso, M J ; Carey, L A ; Cortés, J ; Curigliano, G ; Diéras, V ; El Saghir, N S ; Eniu, A ; Fallowfield, L ; Francis, P A ; Gelmon, K ; Johnston, S R D ; Kaufman, B ; Koppikar, S ; Krop, I E ; Mayer, M ; Nakigudde, G ; Offersen, B V ; Ohno, S ; Pagani, O ; Paluch-Shimon, S ; Penault-Llorca, F ; Prat, A ; Rugo, H S ; Sledge, G W ; Spence, D ; Thomssen, C ; Vorobiof, D A ; Xu, B ; Norton, L ; Winer, E P

Annals of oncology, 2018-08, Vol.29 (8), p.1634-1657 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
7
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
Material Type:
Artigo 		Adicionar ao Meu Espaço

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

Piotrowska, Z. ; Costa, D.B. ; Oxnard, G.R. ; Huberman, M. ; Gainor, J.F. ; Lennes, I.T. ; Muzikansky, A. ; Shaw, A.T. ; Azzoli, C.G. ; Heist, R.S. ; Sequist, L.V.

Annals of oncology, 2018-10, Vol.29 (10), p.2092-2097 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer

Costa, R.B. ; Kurra, G. ; Greenberg, L. ; Geyer, C.E.

Annals of oncology, 2010-11, Vol.21 (11), p.2153-2160 [Periódico revisado por pares]

Oxford: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Loibl, S. ; Jackisch, C. ; Schneeweiss, A. ; Schmatloch, S. ; Aktas, B. ; Denkert, C. ; Wiebringhaus, H. ; Kümmel, S. ; Warm, M. ; Paepke, S. ; Just, M. ; Hanusch, C. ; Hackmann, J. ; Blohmer, J.-U. ; Clemens, M. ; Dan Costa, S. ; Gerber, B. ; Engels, K. ; Nekljudova, V. ; von Minckwitz, G. ; Untch, M.

Annals of oncology, 2017-03, Vol.28 (3), p.497-504 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Material Type:
Artigo 		Adicionar ao Meu Espaço

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Cardoso, F. ; Costa, A. ; Senkus, E. ; Aapro, M. ; André, F. ; Barrios, C.H. ; Bergh, J. ; Bhattacharyya, G. ; Biganzoli, L. ; Cardoso, M.J. ; Carey, L. ; Corneliussen-James, D. ; Curigliano, G. ; Dieras, V. ; El Saghir, N. ; Eniu, A. ; Fallowfield, L. ; Fenech, D. ; Francis, P. ; Gelmon, K. ; Gennari, A. ; Harbeck, N. ; Hudis, C. ; Kaufman, B. ; Krop, I. ; Mayer, M. ; Meijer, H. ; Mertz, S. ; Ohno, S. ; Pagani, O. ; Papadopoulos, E. ; Peccatori, F. ; Penault-Llorca, F. ; Piccart, M.J. ; Pierga, J.Y. ; Rugo, H. ; Shockney, L. ; Sledge, G. ; Swain, S. ; Thomssen, C. ; Tutt, A. ; Vorobiof, D. ; Xu, B. ; Norton, L. ; Winer, E.

Annals of oncology, 2017-01, Vol.28 (1), p.16-33 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.